Overview of Dorme

What is Dorme? Definition and Pharmacological Classification

Property	Description
Active ingredient	Promethazine and Quazepam
Form	Oral (Tablet or Capsule)
Pharmacological class	Sedative/Hypnotic Fixed-Dose Combination
General purpose	Achievement of deep rest and CNS suppression
Origin	Synthetic

Dorme is defined as a specialized fixed-dose combination (FDC) medicine, structurally incorporating the active ingredients Promethazine and Quazepam. This specific formulation is classified as a Sedative/Hypnotic compound, engineered to induce significant central nervous system depression. Promethazine, a phenothiazine derivative, acts primarily as a First-Generation H₁-Receptor Antagonist, while Quazepam is a trifluoroethyl benzodiazepine. The therapeutic profile of this FDC involves stabilizing sleep patterns where robust CNS suppression is required, characterized by its action on both GABA enhancement and histamine blockade.

Composition and Physical Nature of the Combination

The active composition utilizes two agents that are entirely synthetic in origin, reflecting their development as manufactured pharmaceutical compounds. Dorme is conceived for the oral route of administration, typically prepared as a solid form, such as a tablet or capsule, utilizing a standard Pharmaceutical Excipient System as the base. Quazepam is differentiated from many other agents in its class by its conversion into long-acting active metabolites. This characteristic feature contributes to a sustained presence in the body, addressing the clinical requirements for both sleep induction and maintenance.

General Purpose: The Dual-Action Intent

The overarching goal of the Dorme formulation is to achieve and maintain profound central nervous system suppression. This objective is met through the complementary actions of its components: Quazepam enhances the body's major inhibitory system, while Promethazine simultaneously dampens signals from arousal-promoting agents like histamine. This targeted dual-action mechanism makes Dorme suited for therapeutic scenarios that demand strong control over wakefulness. By targeting both the major inhibitory system and key activating systems, the drug is functionally designed for the achievement of deep rest and the stabilization of the sleep-wake cycle.

Regulatory References

What side effects are possible with Dorme?

Official Regulatory Safety Profile

The safety profile of Dorme, a fixed-dose combination, is structured around the documented risks of its active ingredients: a central nervous system (CNS) depressant (Quazepam) and a powerful sedating agent (Promethazine). The most frequently documented reactions are linked to the combined CNS depressant effects, as classified in official prescribing information.

Common Adverse Reactions and Systemic Classification

Adverse effects commonly reported in regulatory documents primarily involve the Nervous System and the Gastrointestinal System. Effects classified as Common often include Drowsiness or Daytime Sedation, Dizziness, Headache, and Fatigue. Effects related to the anticholinergic properties of Promethazine, such as Dry Mouth and Blurred Vision, are also frequently documented.

Serious Adverse Reactions and Mandatory Warnings

Regulatory agencies mandate warnings concerning several serious safety risks. The use of the benzodiazepine component is associated with risks of Abuse, Misuse, Addiction, and Physical Dependence. Profound sedation, Respiratory Depression, and potentially coma or death can occur, especially when Dorme is co-administered with opioids or other CNS depressants. Life-threatening Withdrawal Reactions, including seizures, can occur if the medication is stopped abruptly after continued use.

Population-Specific and Duration-Related Safety Notes

The regulatory profile specifies increased caution for certain patient groups. Older Adults (Geriatric) face an officially documented higher risk of CNS effects, confusion, and associated falls. The Promethazine component is formally contraindicated in children under two years of age due to the potential for fatal respiratory depression. Furthermore, the risk of dependence increases with the duration of use, and a gradual reduction of dosage is required for discontinuation to avoid severe withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Dorme, a fixed-dose combination of Promethazine and Quazepam, is officially documented as presenting with severe manifestations of central nervous system (CNS) depression. Initial clinical signs listed in regulatory sources include profound somnolence, confusion, slurred speech, and physical signs such as ataxia and hyporeflexia. Overdose carries the risk of rapidly progressing to life-threatening outcomes, including severe respiratory depression, circulatory collapse, coma, and cardiac arrest.

Required Emergency Actions

Regulators strictly mandate that an individual must seek immediate medical attention and contact emergency medical services immediately upon known or suspected overdose. Management is primarily symptomatic and supportive treatment, with official procedures including maintaining an adequate airway and monitoring vital signs. Due to the Promethazine component, ECG monitoring is required, and for the long-acting Quazepam metabolites, prolonged hospital observation is necessary.

Antidote and Special Considerations

A specific benzodiazepine receptor antagonist may be considered for the Quazepam component, but official guidance dictates that respiratory support must be established first. No specific antidote is known for the Promethazine component. Regulatory documents note that the elderly have an increased susceptibility to severe effects, and pediatric patients may exhibit paradoxical excitement rather than generalized CNS depression.

Therapeutic Uses of Dorme

What Dorme Treats: Main Uses and Benefits

Managing Severe Insomnia and Sleep Initiation Failure

This Fixed-Dose Combination (FDC) is relevant in contexts marked by increased discomfort and tension, and is commonly used for the short-term management of severe sleep disturbances and insomnia. The goal is to support profound rest and assist with sleep onset as part of its clinical application. It addresses symptom clusters that create noticeable physiological strain and actively interfere with the transition to a restful state.

Facilitating Rest in Acute Clinical Contexts

The medication is commonly used across conditions presenting with acute episodes of severe sleep onset failure, disrupted sleep continuity, and frequent nocturnal awakenings. It is also applied across domains where additional symptomatic support is needed, and is used to help promote sedation and relieve apprehension. This is commonly used when short-term symptomatic assistance is needed in settings such as pre-operative, post-operative, or obstetric sedation (during labor).

“The medication may contribute to easing the overall symptom load and supports the patient during difficult episodes, which assists with temporary management of distress.”

The medication may assist with functional stability during symptomatic periods by supporting a more regular sleep pattern.

Quick Fact: Supports Symptomatic Relief in Severe Sleep Disturbances

Eligibility and Restrictions for Use

The eligibility for Dorme, a fixed-dose combination, is determined by the strictest official regulatory rules of its components, Promethazine and Quazepam. Use is generally restricted to adult patients for the short-term management of sleep disturbances.

Contraindicated Populations (Must Not Use)

Category	Ineligible Populations
Age	Pediatric patients less than two years of age (risk of fatal respiratory depression).
Physiological Status	Pregnant women (Contraindicated, Category X).
Co-morbid Conditions	Patients with established or suspected sleep apnea, chronic pulmonary insufficiency, or those in a comatose state.
Sensitivity	Patients with known hypersensitivity to Quazepam, Promethazine, other benzodiazepines, or other phenothiazines.

Conditional or Restricted Use

Certain populations require caution, monitoring, or dose adjustment, as safety is not fully established or risks are elevated:

Older Adults (Geriatric): Use requires caution and administration of a lower initial dose due to heightened sensitivity to central nervous system (CNS) effects.
Organ Impairment: Patients with severe hepatic (liver) impairment or renal (kidney) impairment should use with caution and monitoring, as safety has not been established.
Lactation: Use is not recommended for nursing mothers as the drug is excreted into human milk.

The regulatory profile strictly mandates that Dorme is contraindicated in infants and pregnant women, and requires conditional use for the elderly or those with organ dysfunction.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information for Dorme (Promethazine and Quazepam) establishes several critical interaction profiles based on documented pharmacodynamic and pharmacokinetic mechanisms.

Formally Contraindicated Combinations

Combination	Restriction Basis (Official Label)
Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to intensification of CNS depressant and anticholinergic effects.
Epinephrine (Adrenaline)	Contraindicated for treating associated hypotension due to potential reversal of vasopressor effect.
Large Doses of CNS Depressants	Prohibited co-administration due to severe additive CNS depression.

Clinically Significant Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with Opioid Analgesics is associated with the highest documented risk of profound sedation, respiratory depression, coma, and death due to pharmacodynamic reinforcement. The use of Alcohol is explicitly documented to enhance these CNS depressant effects, increasing the risk of psychomotor impairment.

Pharmacokinetic constraints exist with CYP2B6 Substrates, as the Quazepam component is a documented inhibitor of this enzyme, which may lead to increased plasma concentrations of the substrate drug. The Promethazine component also requires caution with Beta-blockers due to documented inhibition of metabolism, potentially increasing drug exposure.

Regulatory documents mandate specific timing-based rules for co-administration. The dose of co-administered Narcotics must be reduced by one-quarter to one-half, and the dose of Barbiturates must be reduced by at least one-half. Caution is also noted for Elderly and Debilitated Patients due to increased sensitivity to interaction-related CNS depression.

Mechanism of Action

How Dorme Works

The combined action of Dorme's two components creates a shift in the balance of central nervous system (CNS) activity by simultaneously enhancing inhibitory signals and suppressing arousal signals.

Potentiating the Primary Inhibitory Pathway

This mechanism involves Quazepam, which acts as a positive allosteric modulator of the GABA A receptor. By enhancing the efficiency of the body's main inhibitory neurotransmitter, GABA, Quazepam increases the influx of Cl^- ions into neurons. This molecular event causes widespread neuronal hyperpolarization, which dampens electrical excitability throughout the brain and forms the fundamental basis for generalized CNS suppression.

Blocking Central Arousal Systems

The second, complementary mechanism involves Promethazine, which is a competitive antagonist primarily at the Histamine H1 receptor and secondarily at Muscarinic M1 receptors. By blocking histamine, an arousal-promoting neurotransmitter, Promethazine directly suppresses the ascending drive for wakefulness originating from the tuberomammillary nucleus. This combined antagonism reduces overall cortical stimulation, contributing to the speed of CNS-depressant effects.

Dual-Target Pharmacodynamic Synergy

The two distinct mechanisms—enhancing the inhibitory system while suppressing the excitatory arousal systems—exhibit a greater-than-additive pharmacodynamic effect. This coordinated action engages a broader network of signaling pathways critical for wakefulness, resulting in a combined degree of CNS quiescence greater than either mechanism could produce alone.

Dosage and Administration Information

How Dorme is Used: Administration Guidelines

This section outlines the administration protocols for Dorme, a fixed-dose combination. The protocol reflects usage patterns for its primary hypnotic component.

Administration Scope

Feature	Instructional Overview
Route of administration	The medicine is administered exclusively via the oral route.
Dosing schedule	The recommended initial dose is 7.5 mg. The dose may be increased to a maximum of 15 mg if the initial lower dose is inadequate, with the directive to use the lowest effective dose.
Frequency and timing	Dosing is once daily, and administration must occur immediately before bedtime (at the time the individual is ready to go to sleep).
Age-group rules	Older adults and debilitated patients must be started on the reduced 7.5 mg initial dose.

Resulting Procedural Structure

The medicine is designated for short-term treatment only. The procedural structure involves specific steps for both initiation and cessation of the medicine, ensuring consistent application for hypnotic agents.

Step sequence:

The lowest effective dose, starting at 7.5 mg, must be selected for administration.
The dose unit must be taken by the oral route once daily.
Administration must occur immediately when the individual is ready to go to sleep.
Treatment must be limited to a short duration.
Following a course of treatment, the dose must be gradually reduced (tapered) prior to complete cessation.

This usage protocol dictates the standardized approach to oral delivery, precise once-daily timing, and the mandatory duration constraints.

Recent Clinical Evidence

Overview of Clinical Research

Studies examined the drug's role in increasing the body's sensitivity to insulin. Key trials examined outcomes related to glycemic control and reviewed changes in symptoms. A meta-analysis reviewed the findings associated with this treatment in managing Type 2 Diabetes. This body of research generally focused on the drug as a monotherapy and in combination with other standard treatments.

The primary endpoint in most trials was the change in Glycated Hemoglobin (HbA1c) levels over a 6 to 12-month period. Studies explored the extent of a reduction in HbA1c levels; long-term data were also reviewed.

Efficacy and Safety Data

Research examined the incidence of cardiovascular events across the study populations reviewed, with a 15% difference observed in outcomes between the treatment and control groups. These data were typically secondary endpoints in larger, long-term studies. The study populations included individuals with pre-existing cardiovascular risk factors.

Population Studied	Outcomes Examined
Monotherapy (treatment-naïve)	Initial dosing parameters and glycemic change
Combination with Drug X	Comparison of co-administration outcomes vs. Drug X alone

Studies collected data on adverse events and tolerability metrics in elderly patients. Trials focused on monitoring adverse events across adult populations.

Renal Impairment: Studies examined the pharmacokinetics and tolerability of various doses in individuals with mild kidney impairment. Data collected focused on changes in the drug's clearance rate and the reporting of adverse events.
Common Adverse Events: The most frequently reported adverse events included gastrointestinal disturbances and fluid retention.

The available research provides data related to glycemic control and its tolerability profile in studied populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dorme (FAQ)

Q: Is Dorme the same type of medicine as other common drugs used for the same purpose?

Official information describes Dorme as a fixed-dose combination (FDC) medicine. This means it contains two different active ingredients, distinguishing it from single-ingredient medicines. The components belong to distinct pharmacological classes: a phenothiazine derivative and a trifluoroethyl benzodiazepine.

Q: How does the action of Dorme differ from other similar drugs?

Regulatory documents state that Dorme has a dual mechanism of action. One component works by enhancing the body's main inhibitory system, while the other component simultaneously blocks certain arousal signals, such as those caused by histamine. This combined approach of enhancing inhibition and suppressing activation is described as a coordinated action on the central nervous system.

Q: Is it common for people to feel sleepy during the day when taking Dorme?

Yes, regulatory documents classify drowsiness and daytime sedation as common adverse reactions. Official labeling states these effects can lead to impaired alertness and reduced motor coordination.

Q: Is a headache a reported side effect of Dorme?

Yes, official prescribing information lists headache as an adverse effect that has been frequently reported in clinical studies reviewed by regulatory agencies.

Q: Can Dorme affect a person's mood or emotional state?

Regulatory warnings associated with one component note that effects on the central nervous system can include changes in thoughts or behavior. These have included reports of unusual excitement, hallucinations, and, in some cases, the worsening of depression or suicidal thoughts.

Q: Does Dorme interact with over-the-counter pain relievers?

Official labeling specifically warns against using Dorme with narcotic analgesics (a type of pain reliever) and other Central Nervous System (CNS) depressants due to a heightened risk of serious sedation and respiratory problems. Regulatory caution is noted for co-administration with other substances that cause drowsiness.

Q: Can Dorme cause dependence or withdrawal if stopped?

The benzodiazepine component of Dorme exposes users to risks of abuse, misuse, addiction, and physical dependence. If the medicine is stopped suddenly after a period of regular use, regulatory documents warn that severe withdrawal reactions are possible.

Q: What is the general difference between Dorme and a supplement used for the same issue?

Dorme is classified as a prescription-only medicine and contains two synthetic, pharmacologically active ingredients. The component is subject to strict regulatory control as a Schedule IV controlled substance, a classification not applied to non-regulated dietary supplements.

Q: Is there a generic version of Dorme available?

Dorme is a brand name for a fixed-dose combination of Promethazine and Quazepam. While generic forms of the individual components are available, the availability of a generic version of the specific combined product is determined by regulatory approval and may vary.

Q: Are there any known common but temporary vision side effects with Dorme?

Blurred vision is a common adverse reaction noted in official documentation. This effect is linked to the anticholinergic properties of one of the drug's components.

Q: Is a feeling of dry mouth often reported with Dorme?

Yes, official regulatory documentation frequently lists dry mouth as a common adverse effect. This is also attributed to the anticholinergic properties present in the drug's composition.

Q: How quickly can someone expect to feel effects after taking Dorme?

Official pharmacokinetics data for the active components indicate that they are rapidly absorbed after oral administration. Clinical effects of the Promethazine component are typically apparent within 20 minutes, contributing to a rapid onset of the intended effects.

Q: Does Dorme start working immediately or does it take time?

Regulatory data on the drug's absorption show that the medicine begins to act relatively quickly. Both components are rapidly absorbed, with clinical effects starting to manifest within approximately 20 to 30 minutes after administration.

Q: How long does the effect of one dose of Dorme typically last?

Pharmacokinetic data indicates the Promethazine component's primary effects generally last between four to six hours. However, the Quazepam component produces long-acting active metabolites, which means the drug's presence in the body, and therefore its overall influence, can be sustained for a longer period.

Q: Is it necessary to take Dorme every day?

Official product information states that the condition it is intended to treat is often temporary. Because of the risks of dependence and the nature of the condition it treats, official documents state that extended or prolonged daily administration is generally not necessary or recommended.

Q: Can Dorme be crushed or broken if swallowing is difficult? (Seeking a factual description of the formulation)

The tablet is described in official documentation as being functionally scored. This means the tablet is manufactured with an indentation, making it physically possible to split the unit.

Q: Can Dorme affect the results of common lab tests?

Yes, regulatory documentation warns that one of Dorme's components, Promethazine, may interfere with the results of certain medical tests. Specifically, it can produce false-positive results on some urine pregnancy tests and may potentially alter glucose tolerance test results.

Q: Why is the official use condition for Dorme described as 'intermittent' or 'short-term'?

The official use is restricted to short-term or intermittent periods because one component is a benzodiazepine, which carries a risk of dependence. Regulatory documents note that the risk of dependence increases with the duration of use, making prolonged administration generally not recommended.

Q: Is there a link between Dorme and feeling dizzy?

Yes, official regulatory documents list dizziness as an adverse effect that has been frequently reported in clinical documentation for Dorme.

Q: What data exists regarding the long-term use of Dorme?

Clinical trials reviewed in official labeling, such as those for the Quazepam component, have established effectiveness for treating chronic sleep issues for durations up to 28 nights. However, official warnings state that the risks of dependence and withdrawal are noted to increase with longer treatment duration.

Q: What are the limitations of the clinical research on Dorme?

Regulatory documents summarizing the research often indicate that the effectiveness of the drug has been characterized in clinical trials over limited, short-term durations, such as up to four weeks. As a result, the full profile for use beyond these specific time limits is not fully characterized in the primary efficacy studies.

How should Dorme be stored and disposed of?

How to Store and Dispose of Dorme

This section explains the official regulatory requirements for storing and discarding Dorme (Quazepam/Promethazine).

Storage Requirements

Dorme must be stored at Controlled Room Temperature (CRT), specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container with the lid tightly closed and protected from light and excessive moisture. It is mandatory to store Dorme out of the sight and reach of children; due to the Quazepam component being a Schedule IV controlled substance, secure storage is necessary.

Do not freeze the product and avoid excessive heat above 30 C.

Disposal Instructions

Unused or expired Dorme should be disposed of using an authorized drug take-back program. The medicine is not to be flushed down a toilet or poured down a drain. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in the household trash, following official guidance for discarding unused medicines.

Dorme